Poturoglu S, Ormeci AC, Duman AE. Treatment of pregnant women with a diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(4): 490-502 [PMID: 27867682 DOI: 10.4292/wjgpt.v7.i4.490]
Corresponding Author of This Article
Sule Poturoglu, MD, Department of Gastroenterology, Haseki Training and Research Hospital, 34096 Istanbul, Turkey. sulepot@mynet.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 490-502 Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.490
Treatment of pregnant women with a diagnosis of inflammatory bowel disease
Sule Poturoglu, Asli Ciftcibasi Ormeci, Ali Erkan Duman
Sule Poturoglu, Asli Ciftcibasi Ormeci, Ali Erkan Duman, Department of Gastroenterology, Haseki Training and Research Hospital, 34096 Istanbul, Turkey
Author contributions: Poturoglu S, Ormeci AC and Duman AE contributed equally to this work; Poturoglu S and Ormeci AC performed the literature search, designed and wrote the manuscript; Poturoglu S and Duman AE was responsible for critical revision of the manuscript for important intellectual content.
Conflict-of-interest statement: No conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Sule Poturoglu, MD, Department of Gastroenterology, Haseki Training and Research Hospital, 34096 Istanbul, Turkey. sulepot@mynet.com
Telephone: +90-542-5257271 Fax: +90-212-5896229
Received: March 29, 2016 Peer-review started: April 4, 2016 First decision: May 23, 2016 Revised: August 20, 2016 Accepted: September 21, 2016 Article in press: September 22, 2016 Published online: November 6, 2016 Processing time: 216 Days and 2.4 Hours
Core Tip
Core tip: Active disease prior to conception and during pregnancy increases the rate of pregnancy-related complications; thus, special attention should be given to pregnancy during the disease remission period. The safest drugs for use during pregnancy and breastfeeding are 5-aminosalicylic acid complexes, thiopurines and corticosteroids. Methotrexate and thalidomide are contraindicated. Anti-tumor necrosis factor treatment should be avoided during the third trimester. The risk of venous thromboembolism is increased in patients with moderate-to-severe disease. The delivery method should be selected according to the region of the body involved and disease activity. In this article, the problems encountered by patients with inflammatory bowel disease from pregnancy to breastfeeding are discussed, and appropriate management strategies are suggested.
